{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:41:27Z","timestamp":1774982487838,"version":"3.50.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminoncol.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1053\/j.seminoncol.2017.06.006","type":"journal-article","created":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T03:31:47Z","timestamp":1499484707000},"page":"85-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Current challenges in the management of breast cancer brain metastases"],"prefix":"10.1053","volume":"44","author":[{"given":"Ciara C.","family":"O\u2019Sullivan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole N.","family":"Davarpanah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jame","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1053\/j.seminoncol.2017.06.006_bib1","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","article-title":"CNS metastases in breast cancer","volume":"22","author":"Lin","year":"2004","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1053\/j.seminoncol.2017.06.006_bib2","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2017.06.006_bib3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1309\/AJCPYO5FSV3UPEXS","article-title":"Breast cancer subtypes predispose the site of distant metastases","volume":"143","author":"Soni","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.06.006_bib4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11060-013-1083-9","article-title":"The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer","volume":"112","author":"Sperduto","year":"2013","journal-title":"J Neurooncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.06.006_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11060-016-2075-3","article-title":"Brain metastasis in breast cancer: a comprehensive literature review","volume":"127","author":"Rostami","year":"2016","journal-title":"J Neurooncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2017.06.006_bib6","first-page":"572","article-title":"Updates on the management of breast cancer brain metastases","volume":"28","author":"Lim","year":"2014","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"10.1053\/j.seminoncol.2017.06.006_bib7","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00232-015-9778-9","article-title":"Permeability of the blood-brain barrier: molecular mechanism of transport of drugs and physiologically important compounds","volume":"248","author":"Fong","year":"2015","journal-title":"J Membr Biol"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.06.006_bib8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1124\/dmd.32.1.132","article-title":"Development of a computational approach to predict blood-brain barrier permeability","volume":"32","author":"Liu","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1053\/j.seminoncol.2017.06.006_bib9","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1124\/dmd.112.044719","article-title":"Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp\/Bcrp knockout mice","volume":"40","author":"Agarwal","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1053\/j.seminoncol.2017.06.006_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2013.06.009","article-title":"P-glycoprotein (MDR1\/ABCB1) and breast cancer resistance protein (BCRP\/ABCG2) restrict brain accumulation of the JAK1\/2 inhibitor, CYT387","volume":"76","author":"Durmus","year":"2013","journal-title":"Pharmacol Res"},{"issue":"8","key":"10.1053\/j.seminoncol.2017.06.006_bib11","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1124\/dmd.108.020974","article-title":"Investigation of the role of breast cancer resistance protein (Bcrp\/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse","volume":"36","author":"Giri","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1053\/j.seminoncol.2017.06.006_bib12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/00498254.2014.997324","article-title":"Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats","volume":"45","author":"Huang","year":"2015","journal-title":"Xenobiotica"},{"issue":"11","key":"10.1053\/j.seminoncol.2017.06.006_bib13","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1158\/1535-7163.MCT-13-0132","article-title":"Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model","volume":"12","author":"Mittapalli","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"1-2","key":"10.1053\/j.seminoncol.2017.06.006_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0006-8993(95)00511-N","article-title":"Isolation and culture of human brain microvessel endothelial cells for the study of blood-brain barrier properties in vitro","volume":"692","author":"Biegel","year":"1995","journal-title":"Brain Res"},{"key":"10.1053\/j.seminoncol.2017.06.006_bib15","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.2174\/1381612822666160726113907","article-title":"Targeted vascular drug delivery in cerebral cancer","volume":"22","author":"Humle","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.06.006_bib16","first-page":"289","article-title":"Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study","volume":"17","author":"Morikawa","year":"2015","journal-title":"Neurooncol"},{"issue":"22","key":"10.1053\/j.seminoncol.2017.06.006_bib17","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1002\/cncr.27581","article-title":"Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network","volume":"118","author":"Lin","year":"2012","journal-title":"Cancer"},{"issue":"6","key":"10.1053\/j.seminoncol.2017.06.006_bib18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/annonc\/mdl064","article-title":"Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)","volume":"17","author":"Pestalozzi","year":"2006","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1053\/j.seminoncol.2017.06.006_bib19","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1002\/cncr.27434","article-title":"Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer","volume":"118","author":"Dawood","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.06.006_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(12)70508-9","article-title":"Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial","volume":"14","author":"Goss","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.06.006_bib21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1470-2045(13)70017-2","article-title":"CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)","volume":"14","author":"Pestalozzi","year":"2013","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1053\/j.seminoncol.2017.06.006_bib22","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cncr.23930","article-title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.06.006_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-012-2243-x","article-title":"Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype","volume":"136","author":"Arvold","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1053\/j.seminoncol.2017.06.006_bib24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdn682","article-title":"Survival among women with triple receptor-negative breast cancer and brain metastases","volume":"20","author":"Dawood","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2017.06.006_bib25","first-page":"632","article-title":"Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases","volume":"10","author":"Laimito","year":"2016","journal-title":"Ecancermedicalscience"},{"key":"10.1053\/j.seminoncol.2017.06.006_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1477-7819-9-131","article-title":"Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis","volume":"9","author":"Nishimura","year":"2011","journal-title":"World J Surg Oncol"},{"issue":"6","key":"10.1053\/j.seminoncol.2017.06.006_bib27","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.2010.33.8889","article-title":"Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors","volume":"30","author":"Niikura","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2017.06.006_bib28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bjc.2016.34","article-title":"Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes","volume":"114","author":"Thomson","year":"2016","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1053\/j.seminoncol.2017.06.006_bib29","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.3174\/ajnr.A2397","article-title":"Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma","volume":"32","author":"Hygino da Cruz","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"10.1053\/j.seminoncol.2017.06.006_bib30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas","volume":"9","author":"Brandsma","year":"2008","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2017.06.006_bib31","first-page":"206","article-title":"[Reversible computed tomographic changes following brain tumor irradiation induced by the \"early-delayed reaction\" after radiation]","volume":"26","author":"Fiegler","year":"1986","journal-title":"Radiologe"},{"issue":"18","key":"10.1053\/j.seminoncol.2017.06.006_bib32","first-page":"5950","article-title":"Endothelial apoptosis initiates acute blood-brain barrier disruption after ionizing radiation","volume":"63","author":"Li","year":"2003","journal-title":"Cancer Res"},{"issue":"23","key":"10.1053\/j.seminoncol.2017.06.006_bib33","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1158\/1078-0432.CCR-13-0790","article-title":"CNS metastases in breast cancer: old challenge, new frontiers","volume":"19","author":"Lin","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"30","key":"10.1053\/j.seminoncol.2017.06.006_bib34","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1200\/JCO.2015.60.9503","article-title":"Treatment of brain metastases","volume":"33","author":"Lin","year":"2015","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminoncol.2017.06.006_bib35","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"Jama"},{"issue":"5","key":"10.1053\/j.seminoncol.2017.06.006_bib36","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.3892\/ol.2016.4349","article-title":"Radiotherapy of brain metastases from breast cancer: treatment results and prognostic factors","volume":"11","author":"Kuhnol","year":"2016","journal-title":"Oncol Lett"},{"issue":"34","key":"10.1053\/j.seminoncol.2017.06.006_bib37","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1200\/JCO.2014.58.4367","article-title":"Hippocampal-avoidance whole-brain radiation therapy: a new standard for patients with brain metastases?","volume":"32","author":"Suh","year":"2014","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1053\/j.seminoncol.2017.06.006_bib38","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.30009","article-title":"Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer","volume":"122","author":"Halasz","year":"2016","journal-title":"Cancer"},{"issue":"8","key":"10.1053\/j.seminoncol.2017.06.006_bib39","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199002223220802","article-title":"A randomized trial of surgery in the treatment of single metastases to the brain","volume":"322","author":"Patchell","year":"1990","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminoncol.2017.06.006_bib40","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/(SICI)1097-0142(19961001)78:7<1470::AID-CNCR14>3.0.CO;2-X","article-title":"A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis","volume":"78","author":"Mintz","year":"1996","journal-title":"Cancer"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.06.006_bib41","first-page":"421","article-title":"Assessment of prognostic scores in brain metastases from breast cancer","volume":"16","author":"Tabouret","year":"2014","journal-title":"Neurooncol"},{"issue":"suppl 2","key":"10.1053\/j.seminoncol.2017.06.006_bib42","doi-asserted-by":"crossref","first-page":"ii105","DOI":"10.1093\/annonc\/mdu193.3","article-title":"NAPOLI 1: randomized phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy","volume":"25","author":"Von Hoff","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.06.006_bib43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11060-013-1169-4","article-title":"Systemic treatment after whole-brain radiotherapy may improve survival in RPA class II\/III breast cancer patients with brain metastasis","volume":"114","author":"Zhang","year":"2013","journal-title":"J Neurooncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2017.06.006_bib44","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jsps.2011.12.001","article-title":"The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab)","volume":"20","author":"Sasich","year":"2012","journal-title":"Saudi Pharm J"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.06.006_bib45","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000360930","article-title":"Alleviation of brain edema and restoration of functional independence by bevacizumab in brain-metastatic breast cancer: a case report","volume":"9","author":"Berghoff","year":"2014","journal-title":"Breast Care (Basel)"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.06.006_bib46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/B:CLIN.0000024761.00373.55","article-title":"Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice","volume":"21","author":"Kim","year":"2004","journal-title":"Clin Exp Metastasis"},{"issue":"8","key":"10.1053\/j.seminoncol.2017.06.006_bib47","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1078-0432.CCR-14-2075","article-title":"Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy","volume":"21","author":"Lu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2017.06.006_bib48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/1471-2407-11-395","article-title":"Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death","volume":"11","author":"Le Scodan","year":"2011","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.06.006_bib49","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/annonc\/mdn539","article-title":"Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer","volume":"20","author":"Park","year":"2009","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1053\/j.seminoncol.2017.06.006_bib50","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.2010.12","article-title":"Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer","volume":"87","author":"Dijkers","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.seminoncol.2017.06.006_bib51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ctrv.2016.03.014","article-title":"Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?","volume":"46","author":"Fontanella","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1053\/j.seminoncol.2017.06.006_bib52","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminoncol.2017.06.006_bib53","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","article-title":"Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.06.006_bib54","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s11060-011-0629-y","article-title":"Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases","volume":"105","author":"Lin","year":"2011","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.06.006_bib55","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.06.006_bib56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/bjc.2011.531","article-title":"Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases","volume":"106","author":"Bartsch","year":"2012","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1053\/j.seminoncol.2017.06.006_bib57","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.bjc.6605586","article-title":"Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience","volume":"102","author":"Sutherland","year":"2010","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.06.006_bib58","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10549-013-2754-0","article-title":"A phase I study of lapatinib with whole brain radiotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases","volume":"142","author":"Lin","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.06.006_bib59","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdq434","article-title":"Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine","volume":"22","author":"Metro","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.06.006_bib60","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00280-016-3088-5","article-title":"Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients","volume":"78","author":"Madan","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2017.06.006_bib61","first-page":"42","article-title":"Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors","volume":"4","author":"O'Sullivan","year":"2014","journal-title":"Front Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2017.06.006_bib62","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4161\/cc.5.9.2713","article-title":"The basal phenotype of BRCA1-related breast cancer: past, present and future","volume":"5","author":"Tischkowitz","year":"2006","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.06.006_bib63","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/bjp.2008.260","article-title":"Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2","volume":"155","author":"Regina","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.seminoncol.2017.06.006_bib64","unstructured":"Angiochem's ANG1005 shows clinical benefits and prolonged survival for breast cancer patients with brain metastases. Available at: http:\/\/angiochem.com\/angiochems-ang1005-shows-clinical-benefits-and-prolonged-survival-breast-cancer-patients-brain."},{"issue":"9","key":"10.1053\/j.seminoncol.2017.06.006_bib65","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1158\/1535-7163.MCT-12-0061","article-title":"TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells","volume":"11","author":"Fitzgerald","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1053\/j.seminoncol.2017.06.006_bib66","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/jps.23994","article-title":"Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx,((R))\/Doxil((R))--a cerebral open flow microperfusion pilot study","volume":"103","author":"Birngruber","year":"2014","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1053\/j.seminoncol.2017.06.006_bib67","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1080\/14656566.2016.1201072","article-title":"CDK4\/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update","volume":"17","author":"O'Sullivan","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1053\/j.seminoncol.2017.06.006_bib68","doi-asserted-by":"crossref","first-page":"67","DOI":"10.14694\/EdBook_AM.2015.35.67","article-title":"Targeted and immunotherapeutic approaches in brain metastases","author":"Ahluwalia","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"12","key":"10.1053\/j.seminoncol.2017.06.006_bib69","doi-asserted-by":"crossref","first-page":"8448","DOI":"10.4049\/jimmunol.177.12.8448","article-title":"NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain","volume":"177","author":"Prins","year":"2006","journal-title":"J Immunol"},{"issue":"5","key":"10.1053\/j.seminoncol.2017.06.006_bib70","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2017.06.006_bib71","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.06.006_bib72","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.06.006_bib73","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13058-016-0702-8","article-title":"Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1\/PD-L axis","volume":"18","author":"Duchnowska","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"10","key":"10.1053\/j.seminoncol.2017.06.006_bib74","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1158\/1078-0432.CCR-13-2588","article-title":"Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner","volume":"20","author":"Palmieri","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.06.006_bib75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00109-014-1226-2","article-title":"Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns","volume":"93","author":"Zimmer","year":"2015","journal-title":"J Mol Med (Berl)"},{"issue":"8","key":"10.1053\/j.seminoncol.2017.06.006_bib76","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clon.2015.04.033","article-title":"A prospective randomised phase III clinical trial testing the role of prophylactic cranial radiotherapy in patients treated with trastuzumab for metastatic breast cancer - Anglo Celtic VII","volume":"27","author":"Canney","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.06.006_bib77","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/ctrv.1999.0119","article-title":"Leptomeningeal carcinomatosis","volume":"25","author":"Grossman","year":"1999","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2017.06.006_bib78","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clbc.2016.07.014","article-title":"Optimal management of leptomeningeal carcinomatosis in breast cancer patients-a systematic review","volume":"16","author":"Dudani","year":"2016","journal-title":"Clin Breast Cancer"},{"issue":"18","key":"10.1053\/j.seminoncol.2017.06.006_bib79","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.ejca.2004.08.012","article-title":"The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study","volume":"40","author":"Boogerd","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2017.06.006_bib80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clbc.2016.07.002","article-title":"Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis","volume":"17","author":"Morikawa","year":"2016","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"10.1053\/j.seminoncol.2017.06.006_bib81","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-005-9044-6","article-title":"Systemic high-dose intravenous methotrexate for central nervous system metastases","volume":"78","author":"Lassman","year":"2006","journal-title":"J Neurooncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2017.06.006_bib82","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","article-title":"High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?","volume":"16","author":"Glantz","year":"1998","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2017.06.006_bib83","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.2000.18.11.2349","article-title":"Trastuzumab in CSF","volume":"18","author":"Pestalozzi","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2017.06.006_bib84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40425-015-0084-y","article-title":"Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient","volume":"3","author":"Lu","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1053\/j.seminoncol.2017.06.006_bib85","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4143\/crt.2014.234","article-title":"Intrathecal Trastuzumab treatment in patients with breast cancer and leptomeningeal carcinomatosis","volume":"48","author":"Park","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.06.006_bib86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-013-2525-y","article-title":"Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis","volume":"139","author":"Zagouri","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"10.1053\/j.seminoncol.2017.06.006_bib87","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1200\/JCO.2012.44.8894","article-title":"Intrathecal trastuzumab halts progression of CNS metastases in breast cancer","volume":"34","author":"Bousquet","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2017.06.006_bib88","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11912-011-0204-x","article-title":"Clinical trial design in brain metastasis: approaches for a unique patient population","volume":"14","author":"Peereboom","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"10.1053\/j.seminoncol.2017.06.006_bib89","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrclinonc.2011.73","article-title":"Medical oncology: patients with brain metastases in early-phase trials","volume":"8","author":"Marko","year":"2011","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775417300611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775417300611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T08:50:17Z","timestamp":1535619017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775417300611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0093775417300611"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2017.06.006","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current challenges in the management of breast cancer brain metastases","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2017.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}